Why Compare Wegovy Starter Dose Against Mounjaro?
Understanding Wegovy Starter Dose vs Mounjaro Mechanisms
The fundamental difference between Wegovy's starter dose and Mounjaro lies in their active ingredients and how they work in your body. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the natural fullness hormone your intestines produce after eating. Mounjaro contains tirzepatide, which targets both GIP and GLP-1 receptors, creating what researchers call a "dual incretin" approach to appetite regulation.
When considering the Wegovy starter dose journey, you begin at 0.25mg for four weeks before escalating to 0.5mg, then 1mg, 1.7mg, and finally 2.4mg maintenance. Mounjaro follows a different path, starting at 2.5mg for four weeks, then increasing through 5mg, 7.5mg, 10mg, 12.5mg, up to 15mg maximum. Both require prescription-only medicine status and clinical assessment before supply.
Wegovy Starter Dose vs Mounjaro Pricing Comparison
The Wegovy starter dose at 0.25mg costs £79.99 through EverydayMeds, while Mounjaro's starting dose of 2.5mg is priced differently to reflect the distinct medication formulations. New customers can apply discount code FIRST40 at checkout, with returning customers using DOSE25. Our Intro Duo bundle combines Wegovy's first two doses (0.25mg and 0.5mg) for £169.99, providing eight weeks of treatment during the initial escalation phase.
As you progress through the Wegovy starter dose schedule, subsequent pens cost £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), and £209.99 for the 2.4mg maintenance dose. Bundle options like the Intro Trio (first three doses) cost £299.99, offering convenience through fewer orders and Reliable Supply continuity. Both medications require ongoing monthly costs as weight management represents a long-term commitment rather than a short-term intervention.
Clinical Evidence Behind Wegovy Starter Dose Selection
The Wegovy starter dose protocol emerged from the STEP clinical trial programme, which demonstrated that gradual dose escalation helps minimise gastrointestinal side effects while optimising therapeutic benefits. In clinical trials, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks in the STEP 1 trial (Wilding et al., NEJM, 2021). The starter dose approach allows your body to adapt to semaglutide's effects on gastric emptying and appetite centres.
Mounjaro's clinical development followed the SURMOUNT trial series, showing that tirzepatide's dual-hormone approach may support weight management through complementary pathways. However, comparing trial results directly isn't appropriate due to different study designs, patient populations, and methodologies. Both medications demonstrated efficacy when combined with lifestyle interventions, supporting their approval by the MHRA for weight management in eligible adults.
How Wegovy Starter Dose Prepares Your System
The Wegovy starter dose of 0.25mg serves as an introduction period, allowing your GLP-1 receptors to adapt to semaglutide stimulation without overwhelming your digestive system. This prescription-only medicine works by slowing gastric emptying, which means food stays in your stomach longer, promoting earlier satiety signals. The gradual escalation from the starter dose through to 2.4mg maintenance helps your body adjust to these physiological changes. Most patients find the starter dose well-tolerated, though some experience mild nausea as their system adapts to the medication's appetite-regulating effects. Your prescriber monitors this progression to ensure optimal dosing for your individual response and tolerance levels.
EverydayMeds Ordering Process for Both Medications
Accessing either Wegovy starter dose or Mounjaro through EverydayMeds begins with our 3-minute online clinical assessment, designed to evaluate your suitability for prescription weight management medication. Our qualified prescribers review your submission within 3 working days (or 24 hours with express service), checking factors like BMI, weight-related health conditions, and contraindications. Once approved, your medication ships via next-day cold-chain delivery, maintaining the 2-8°C temperature requirements essential for both semaglutide and tirzepatide stability. Our GPhC-registered pharmacy (#9012878) ensures you receive authentic medication directly from licensed UK suppliers. The process includes ongoing prescriber support as you progress through your chosen medication's dosing schedule.
Storage and Practical Considerations for Wegovy Starter Dose
Wegovy pens must be stored in the refrigerator at 2-8°C before first use, but offer superior travel flexibility compared to Mounjaro once removed from cold storage. Your Wegovy starter dose pen can remain at room temperature (below 30°C) for up to 6 weeks, while Mounjaro only maintains stability for 21 days under similar conditions. The FlexTouch pen design makes weekly injections straightforward, with clear dosing windows and simple operation. Each pen contains four doses, meaning your starter dose pen lasts exactly four weeks before progressing to the next strength. This storage advantage makes Wegovy particularly suitable for frequent travellers or those with limited refrigerator access during holidays or work trips.
Wegovy Starter Dose Escalation vs Mounjaro Titration Schedule
The Wegovy starter dose represents the beginning of a carefully designed five-step escalation protocol spanning 16 weeks before reaching maintenance dosing. This gradual approach contrasts with Mounjaro's six-dose titration schedule, which also spans approximately 20 weeks to reach maximum dosing if clinically appropriate. Neither medication allows dose-skipping, as both manufacturers designed their escalation schedules to optimise tolerance and efficacy based on extensive clinical testing.
Your prescriber determines progression timing based on your individual response, side effect profile, and weight management goals. Some patients remain on intermediate doses if achieving satisfactory results, while others require the full maintenance dose for optimal benefit. The structured approach of both medications ensures systematic evaluation of your response at each dose level, supporting personalised treatment decisions throughout your weight management journey.
Making Your Choice: Wegovy Starter Dose or Mounjaro
Selecting between Wegovy's starter dose pathway and Mounjaro depends on multiple factors your prescriber will evaluate during clinical assessment. Individual response to GLP-1-based medications varies, and some patients may find single-hormone targeting (Wegovy) more suitable than dual-hormone activation (Mounjaro). Practical considerations like storage requirements, injection frequency, and cost progression through dose escalation also influence decision-making. Both medications are available through EverydayMeds following appropriate clinical evaluation, with our prescribers helping determine the most suitable option based on your specific circumstances. Remember that weight management represents a long-term commitment requiring ongoing medication alongside sustained lifestyle changes including reduced-calorie diet and increased physical activity. Visit https://everydaymeds.co.uk/collections/weight-loss to begin your clinical assessment and discuss both options with our qualified prescribers today.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
